Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

1(33.3%)

Phase 3

1(33.3%)

Phase 1

1(33.3%)

3Total

Phase 2(1)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06095947Completed

Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years

Role: lead

NCT06334510Completed

Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.

Role: lead

NCT06177249Phase 3Completed

To Evaluate the Immunogenicity and Safety of Two Different Immunization Schedules of Rabies Vaccine (Vero Cell)

Role: lead

NCT03196661Phase 1Completed

Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population

Role: lead

NCT00975572Phase 2Completed

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older

Role: collaborator

NCT01096225Unknown

Immunogenicity Study of S-OIV H1N1 Influenza Vaccine

Role: collaborator

All 6 trials loaded